(Q79261035)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Cost-Effectiveness of Hepatitis A/B Vaccine versus Hepatitis B Vaccine in Public Sexually Transmitted Disease Clinics (English)

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

cost-effectiveness analysis

29 March 2024

main subject

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

29 March 2024

author name string

R. Jake Jacobs

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603096

29 March 2024

Allen S. Meyerhoff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14603096

29 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14603096

29 March 2024

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

Sexually Transmitted Diseases

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

859-865

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

The cost of hepatitis A infections in American adolescents and adults in 1997.

20 December 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates

29 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Transmission of hepatitis A through household contact.

29 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual

29 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team

29 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Heterosexual genital sexual activity among adolescent males: 1988 and 1995.

29 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Hepatitis B vaccination in sexually transmitted disease (STD) clinics: a survey of STD programs

29 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries

29 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Cost-effectiveness analysis of hepatitis A vaccination strategies for adults

29 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

The Markov process in medical prognosis.

29 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Sexual transmission and prevention of the hepatitis viruses A-E and G

29 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization

29 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Acceptance of hepatitis B vaccination among adult patients with sexually transmitted diseases

29 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Improving hepatitis B immunization among high-risk adolescents: a low-cost intervention on the Mexico-United States border

29 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Routine hepatitis B vaccination in a clinic for sexually transmitted diseases

29 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Hepatitis B vaccination and screening for markers at a sexually transmitted disease clinic for men

29 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

29 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

29 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule).

29 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

29 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Qualitative Research: Consensus methods for medical and health services research

29 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

29 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement

29 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

29 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys

29 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction

29 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program

29 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis

29 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

29 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus

29 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam

29 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Benefits and costs of using HPV testing to screen for cervical cancer

29 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Cost-effectiveness of pneumococcal vaccine

29 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

A statewide hepatitis B vaccination program for school children in Hawaii: vaccination series completion and participation rates over consecutive school years

29 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

The cost of a food-borne outbreak of hepatitis A in Denver, Colo

29 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Control of hepatitis A through routine vaccination of children

29 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

Lack of evidence for increased risk of hepatitis A infection in homosexual men

29 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/01.OLQ.0000086601.18907.47

29 March 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14603096%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference